Short answer: BPC-157 is a 15-amino-acid synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, derived from a larger body protective compound first isolated from human gastric juice. The pre-clinical literature (overwhelmingly rat and mouse studies) reports effects on angiogenesis, nitric oxide system modulation, fibroblast migration and gastrointestinal ulcer healing. No FDA approval exists; human trials are limited. It is most often studied alongside TB-500 in the so-called “Wolverine” research stack. New-U catalogues BPC-157 as a lyophilised reference peptide on the Healing & Recovery shelf - sealed vials, per-batch CoA, research use only.
BPC-157 is the most-searched non-GLP-1 peptide on the internet - approximately 165,000 monthly Google queries in the United States alone, and the fastest-growing search term in the regenerative-research literature. It has accumulated more pre-clinical citations than almost any other research peptide on the shelf, but its human-trial record remains thin and the FDA explicitly raised concerns about its safety data in the 2023 compounding decision. This guide explains the molecule, what the animal-study evidence actually claims, where the human-data gap sits, and how research-grade BPC-157 is posted on the New-U catalogue. For the tattoo-recovery-specific angle (a controlled dermal-injury context), see BPC-157 & tattoo healing.
Plain-English summary. BPC-157 is a research peptide. The bench-science literature is interesting; the human evidence is not yet there. New-U sells it as a lyophilised reference reagent labelled research use only, not for human consumption, with no dosing or therapeutic guidance. This page is general information, not legal or medical advice; do not use unapproved peptides on people.
BPC-157 is a pentadecapeptide - the prefix means a peptide of 15 amino acids - with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to residues 14–28 of a larger 62-residue “Body Protective Compound” that was first isolated from human gastric juice by the Sikiric group in Zagreb, Croatia in the 1990s. The synthetic short form is structurally simple, contains no rare residues, and is unusually stable in solution at gastric pH - which is the property that drove early oral-research interest.
Molecular weight is ~1,419 Da. The peptide is non-glycosylated, non-lipidated, and has no formal post-translational modifications. By peptide standards it is small, cheap to synthesise, and forgiving in storage.
The published mechanism is a constellation of effects rather than a single receptor target. The most-cited threads:
None of those mechanisms have been demonstrated in randomised human trials of meaningful size. The most-cited reviews are catalogued under PubMed: BPC-157, and a recent narrative review of the regenerative-research literature is at PMC12446177.
This is the part that any honest research-side write-up has to say plainly: BPC-157 does not have a robust human evidence base. The published human clinical-trial record is minimal. There are case reports, anecdotal series, and a handful of small open-label studies, but no large randomised controlled trials of the kind that would inform regulatory approval. The 2023 FDA compounding decision flagged exactly this gap: BPC-157 has not generated the human safety data required to move it into the bulk-compounding category. The full FDA framing is explained in The 2023 FDA Peptide Compounding Decision.
What the pre-clinical literature describes is interesting and warrants further investigation; it is not equivalent to clinical evidence. The research-compound framing on this site exists precisely because the molecule sits in that “promising-but-not-clinically-proven” band.
In the regenerative-research literature, BPC-157 is most commonly studied alongside TB-500 (a synthetic fragment of thymosin β-4). The pairing is mechanistic, not marketing: the two peptides appear to act through non-overlapping pathways.
The combination is sometimes informally referred to as the “Wolverine stack” in trade-press writing. That is a description of how the two peptides have been studied together, not a human dosing protocol. For the tendon and ligament repair animal-study angle, see our tattoo-healing research note (which discusses BPC-157 in a controlled dermal-injury context).
| Jurisdiction | BPC-157 status |
|---|---|
| United States (FDA) | No approval. 2023 compounding decision did not move it into 503A bulk. |
| United Kingdom (MHRA) | No marketing authorisation. Research-compound framing applies. |
| European Union (EMA) | No marketing authorisation. |
| Australia (TGA) | No registration. |
| WADA | Listed on the World Anti-Doping Agency Prohibited List under category S0 (non-approved substances). |
The WADA listing is worth noting independently - it does not change the legal-supply position, but any researcher working with samples that may overlap with athletic populations should be aware of it.
On the New-U catalogue, BPC-157 is listed on the Healing & Recovery shelf as a lyophilised reference peptide. Sealed glass vial, lyophilised under nitrogen, for laboratory use only.
Lyophilised BPC-157 is unusually stable for a peptide of its size - the proline-rich sequence has no oxidation-prone residues and no labile post-translational modifications. Store sealed vials at −20°C for long-term storage; brief room-temperature excursions during shipment are tolerated. Once reconstituted (typically in bacteriostatic water for research handling), store at 2–8°C and protect from light. Reconstituted BPC-157 is among the more stable peptides in the catalogue but still benefits from being used within a research-relevant time window. Full reference: How to Store Peptides. For mg-to-mL maths: reconstitution calculator.
For a 15-amino-acid, proline-rich peptide:
BPC-157 is one of the most counterfeited peptides on the supply side precisely because it is cheap to synthesise - which means an unscrupulous supplier could substitute a less-pure batch and the visual product would look identical. The CoA is the only verification.
Walk away from any BPC-157 listing that:
What is BPC-157?
A 15-amino-acid synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a fragment of a body protective compound first isolated from human gastric juice. Pre-clinical literature reports angiogenic, anti-inflammatory and tissue-migration effects in animal models.
Is BPC-157 FDA-approved?
No. The 2023 FDA compounding decision reviewed BPC-157 and the agency did not move it into the 503A bulk-compounding category. It has no marketing authorisation in any jurisdiction.
What does the BPC-157 research evidence actually show?
Overwhelmingly animal studies. Reports include accelerated rat tendon-fibroblast migration, gastric ulcer healing, and CNS-injury effects. Human trials are limited and the FDA has highlighted the absence of robust human safety data.
Is the “Wolverine stack” with TB-500 a real protocol?
It is a research framing describing how the two peptides have been studied alongside each other in animal regeneration models - their mechanisms (BPC-157 on angiogenesis, TB-500 on cell motility) are non-overlapping. It is not a human dosing protocol.
Is BPC-157 a research compound on this site?
Yes. New-U catalogues BPC-157 as a lyophilised reference peptide with a per-batch Certificate of Analysis. Sold research use only, not for human consumption.
External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.
New-U Research Compounds catalogues BPC-157 as lyophilised reference peptide - sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with a per-batch Certificate of Analysis. Tracked worldwide delivery. Research use only - not for human consumption.
View BPC-157